European Study on Next-Generation and Conventional Imaging in Men With Advanced Prostate Cancer

What this Trial Is About

Researchers are collecting real-world data on advanced prostate cancer to evaluate the role of next-generation imaging NGI, such as PETCT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. This study focuses on men aged 18 or older with confirmed prostate cancer who need imaging to assess possible metastases either at diagnosis or after relapse. It aims to understand when NGI should be used, how it influences treatment decisions, and its impact on patient outcomes. Participants will receive standard care without experimental treatments. Imaging will be done using either conventional methods, NGI, or both, according to local clinical practice and guidelines. The study includes a cross-sectional observation to evaluate imaging benefits and a longitudinal observation to assess survival outcomes and treatment response based on the imaging approach used. During the study, data will be collected from medical records including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will track the proportion of patients requiring each imaging type and changes in treatment prompted by imaging results within 4 to 6 weeks. The study involves no additional procedures beyond routine care, and participation will continue until the study end in December 2026.

European Registry of Next Generation Imaging in Advanced Prostate Cancer